drugset
drugset / Trial / NCT00003441

Irofulven in Treating Patients With Metastatic Colorectal Cancer

NCT00003441 ↗

Phase 2 Completed 26 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with metastatic colorectal cancer.

Timeline

Start
1998-08
Primary completion
2000-11-08
Completion
2000-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject irofulven Small molecule — Intravenous

Indications

colorectal cancer